COVID-19 Soliris Expanded Access Protocol
NCT04802083 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-10-04
Summary
This protocol provides participants with COVID-19 access to Soliris.
Conditions
- Covid19
Interventions
- BIOLOGICAL
-
Eculizumab 900-1200 mg will be administered intravenously.
Sponsors & Collaborators
-
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
NCT02082899 ·Status: COMPLETED ·Phase: PHASE2
-
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
NCT07118241 ·Status: RECRUITING ·Phase: PHASE2
-
Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome
NCT03865888 ·Status: COMPLETED ·Phase: PHASE3
-
Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome
NCT00542763 ·Status: COMPLETED ·Phase: PHASE1
-
RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
NCT06520202 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease
NCT04608084 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
NCT01421498 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
NCT00901693 ·Status: TERMINATED ·Phase: PHASE2
-
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
NCT01382225 ·Status: COMPLETED ·Phase: PHASE3
-
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
NCT04206020 ·Status: COMPLETED ·Phase: PHASE3
-
Pack Cross Linking for Infectious Keratitis
NCT05881187 ·Status: UNKNOWN ·Phase: NA
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
NCT01320553 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of the VEGA UV-A System to Treat Ectasia
NCT01398839 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.
NCT03698045 ·Status: WITHDRAWN ·Phase: PHASE1
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
NCT04819269 ·Status: COMPLETED ·Phase: PHASE3
-
Nasal Spray Study in Sjogren's Dry Eye Disease
NCT05700422 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
NCT00198536 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
NCT06381986 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment
NCT00438048 ·Status: COMPLETED ·Phase: PHASE4
-
Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis
NCT04275232 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome
NCT06831253 ·Status: RECRUITING ·Phase: NA
-
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
NCT04030962 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
NCT01877694 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis
NCT01243983 ·Status: COMPLETED ·Phase: PHASE3
-
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
NCT05636228 ·Status: COMPLETED ·Phase: PHASE2